All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency
A Phase 1 Study to Evaluate the Safety of BB2121 in Subjects with High Risk Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)
Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients: inflammatory mechanisms
Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1(RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety And Tolerability Study Of AO-176 As Monotherapy And In Combination With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma
Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortexomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse
Mortality after Allogeneic Transplantation in Older Adults
Mortality after Allogeneic Transplantation in Older Adults
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination with Backbone Regimens for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
If you are eligible to participate in this study, you will be assigned to receive either:
1) Arm A: TAK-079 (study medication), lenalidomide and dexamethasone (backbone regimen)
or
2) Arm B: TAK-079 (study medication), bortezomib, lenalidomide and dexamethasone (backbone regimen)